Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IMT-009 + fruquintinib
- Development stage
- Unknown
- Lead developer
- Immunitas Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
IMT-009 + fruquintinib is an investigational combination therapy consisting of IMT-009, a monoclonal antibody targeting CD161, and fruquintinib, an oral small molecule inhibitor that blocks vascular endothelial growth factor receptors (VEGFR). IMT-009 is designed to modulate immune responses by binding to CD161, which is expressed on certain immune cells, potentially enhancing anti-tumor immunity. Fruquintinib acts as an anti-angiogenic agent by inhibiting VEGFRs, thereby blocking the blood supply to tumors. This combination is currently being evaluated for safety, tolerability, and preliminary efficacy in patients with relapsed or refractory Hodgkin lymphoma and T-cell lymphoma in phase 1 and phase 2 clinical trials. IMT-009 is developed by Immunitas Therapeutics, while fruquintinib is developed by HUTCHMED and marketed as Fruzaqla by Takeda in the United States for metastatic colorectal cancer[1][2][3][4].
- Other names
- IMT-009 and fruquintinib combinationIMT009 and fruquintinib combinationIMT 009 and fruquintinib combination
02
Targets
KLRB1 (C-type lectin-like receptor CD161)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR3 (Vascular endothelial growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)FGFR1 (Fibroblast growth factor receptor 1)RET (Rearranged during transfection receptor tyrosine kinase)
Beyond the preview
Go deeper on IMT-009 + fruquintinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IMT-009 + fruquintinib.